Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02782104 · ClinicalTrials.gov registry record · Phase 3

A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

A Phase 3 study of Depressive Disorder, Treatment-Resistant, sponsored by Janssen Research & Development.

Completed
Registry status
Phase 3
Development phase
1,148
Enrollment target
20
Study locations

NCT02782104 is a Phase 3 study of Depressive Disorder, Treatment-Resistant that has completed, run by Janssen Research & Development. The registered enrollment target is 1,148 participants, above the 110-participant average among 9 other Depressive Disorder, Treatment-Resistant trials with a reported enrollment target (944% higher). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02782104, a Phase 3 study of Depressive Disorder, Treatment-Resistant, has completed, sponsored by Janssen Research & Development.

COMPLETED
Registry status
Phase 3
Development phase
1,148 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the safety and tolerability of esketamine nasal spray in participants with treatment-resistant depression (TRD).

Conditions Studied

Depressive Disorder, Treatment-Resistant

Interventions

  • DRUG Esketamine Nasal Spray

Study Locations (20)

California

  • - Garden Grove
  • - Glendale
  • - Oakland
  • - Orange
  • - San Diego
  • - San Rafael

Illinois

  • - Chicago
  • - Hoffman Estates
  • - Joliet
  • - Maywood
  • - Skokie

Florida

  • - Gainesville
  • - Miami
  • - Orlando

Connecticut

  • - Hartford
  • - New Haven

Alabama

  • - Birmingham

Arkansas

  • - Little Rock

Georgia

  • - Atlanta

Iowa

  • - Iowa City

Trial Details

FieldValue
Enrollment Target 1,148 participants
Start Date 2016-06-09
Est. Completion 2022-12-30
Phase Phase 3

Sponsor

Janssen Research & Development

593 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02782104

The ClinicalTrials.gov registry entry for NCT02782104 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,148 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 110-participant average among 9 other Depressive Disorder, Treatment-Resistant trials with a reported enrollment target (944% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Depressive Disorder, Treatment-Resistant appearing as the primary indexed condition, and to 1 intervention - of which Esketamine Nasal Spray is the first listed.

NCT02782104 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Illinois, Florida.

Frequently Asked Questions

What is clinical trial NCT02782104 about?

NCT02782104 is a clinical study titled "A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression". The purpose of this study is to assess the safety and tolerability of esketamine nasal spray in participants with treatment-resistant depression (TRD).

What is the current status of trial NCT02782104?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,148 participants. The study started on 2016-06-09. Estimated completion is 2022-12-30.

What conditions does trial NCT02782104 study?

This clinical trial studies the following conditions: Depressive Disorder, Treatment-Resistant.

What interventions are being tested in trial NCT02782104?

The interventions under investigation include: Esketamine Nasal Spray (DRUG).

Who is sponsoring clinical trial NCT02782104?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02782104 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Depressive Disorder, Treatment-Resistant

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Depressive Disorder, Treatment-Resistant

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.